By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


Company News
Soligenix (SNGX) To Present At 2016 Aegis Growth Conference 9/15/2016 10:53:59 AM
Soligenix (SNGX) And SciClone (SCLN) Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis 9/12/2016 6:23:01 AM
Soligenix (SNGX) Announces Issuance Of New Composition Of Matter Patent For Dusquetide Analogs 9/6/2016 8:24:22 AM
FDA Grants Soligenix (SNGX) Orphan Drug Designation For Dusquetide For Treatment Of Macrophage Activation Syndrome 8/18/2016 6:46:19 AM
Soligenix (SNGX) Announces Recent Accomplishments And Second Quarter 2016 Financial Results Highlighted By Revenues Of $3.2 Million 8/11/2016 10:07:34 AM
Soligenix (SNGX) Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield In GI ARS 7/25/2016 6:45:50 AM
Soligenix (SNGX) Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation 7/18/2016 6:24:58 AM
Soligenix (SNGX) Taps a New CFO 6/20/2016 6:00:52 AM
Soligenix (SNGX) Announces Presentation Of Phase 2 Oral Mucositis Clinical Trial Results At The 2016 Multinational Association For Supportive Care In Cancer Conference 6/6/2016 11:22:09 AM
Soligenix (SNGX) Release: FDA Grants Soligenix "Fast Track" Designation For SGX943 For The Treatment Of Melioidosis 5/31/2016 7:35:07 AM